FDA Spells Out ‘Refusal to File’ Scenarios for NDAs and BLAs

Drug Industry Daily
A A
The FDA issued draft guidance on when CDER may refuse to file new drug applications and biologics license applications, outlining errors or omissions that can lead them to classify the application as incomplete.

To View This Article:

Login

Subscribe To Drug Industry Daily